v3.26.3
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Total revenue $ 2,804.1 $ 2,534.7 $ 8,017.9 $ 7,611.2
Cost and expenses:        
Cost of sales, excluding amortization and impairment of acquired intangible assets 748.4 674.4 2,186.3 1,908.7
Research and development 574.0 436.1 1,642.6 1,269.2
Acquired in-process research and development, upfront and milestone expense 283.8 2.1 481.8 249.4
Selling, general and administrative 752.0 594.8 2,069.0 1,751.1
Amortization and impairment of acquired intangible assets 172.8 135.7 477.5 378.4
Collaboration profit sharing/(loss reimbursement) 77.8 87.2 220.8 220.3
(Gain) loss on fair value remeasurement of contingent consideration 0.4 5.6 23.4 28.4
Restructuring charges 66.5 7.4 239.8 42.0
Other (income) expense, net 137.4 34.1 175.6 151.2
Total cost and expense 2,813.1 1,977.4 7,516.8 5,998.7
(Loss) Income before income tax (benefit) expense (9.0) 557.3 501.1 1,612.5
Income tax (benefit) expense 11.6 90.8 104.7 270.7
Net (loss) income attributable to Biogen Inc. $ (20.6) $ 466.5 $ 396.4 $ 1,341.8
Net (loss) income per share:        
Basic earnings per share attributable to Biogen Inc. (in USD per share) $ (0.14) $ 3.18 $ 2.69 $ 9.16
Diluted earnings per share attributable to Biogen Inc. (in USD per share) $ (0.14) $ 3.17 $ 2.66 $ 9.14
Weighted-average shares used in calculating:        
Basic earnings per share attributable to Biogen Inc. (in USD per share) 147,800 146,600 147,500 146,400
Diluted earnings per share attributable to Biogen Inc. (in USD per share) 147,800 147,100 148,900 146,800
Product revenue, net        
Total revenue $ 2,088.7 $ 1,846.9 $ 5,757.4 $ 5,452.1
Revenue from anti-CD20 therapeutic programs        
Total revenue 497.3 493.9 1,429.9 1,339.4
Alzheimer's collaboration revenue        
Total revenue 68.4 42.7 191.6 130.6
Contract manufacturing, royalty and other revenue        
Total revenue $ 149.7 $ 151.2 $ 639.0 $ 689.1